Finance

Lists
BHC:NYSE
Bausch Health Companies Inc
$5.67
+0.35%
(+0.020) 1D
$5.78
+1.94% (+0.11)
After hours
Closed: Sep 18, 4:00:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BHC...
Open
$5.68
High
$5.72
Low
$5.60
Mkt. cap
2.13B
Avg. vol.
2.73M
Volume
1.91M
52-wk high
$8.00
52-wk low
$4.33
EPS
-$2.96
Beta
0.37
Shares outstanding
373.99M
No. of employees
20K
Open
$5.68
High
$5.72
Low
$5.60
Mkt. cap
2.13B
Avg. vol.
2.73M
Volume
1.91M
52-wk high
$8.00
52-wk low
$4.33
EPS
-$2.96
Beta
0.37
Shares outstanding
373.99M
No. of employees
20K
News stories
From web sources and news partners
Profile
Bausch Health Companies Inc. is a global, diversified Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic pharmaceuticals, and over-the-counter products directly or indirectly in more than 90 countries and regions, including the United States, Canada, Europe, the Middle East, Africa, Asia Pacific and Latin America. Wikipedia
About Bausch Health Companies Inc
CEOThomas J. Appio
Employees20.3K
Founded1959
HeadquartersLaval, Quebec, Canada
SectorPharmaceutical industry
Websitebauschhealth.com
Analyst ratings
Based on 1 analyst giving stock ratings to BHC in the past 3 months
Hold
Buy
0
Hold
1
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for BHC in the last 3 months
Highest
Current $5.67
$9.00 (+58.73%)
Average
$9.00 (+58.73%)
Lowest
$9.00 (+58.73%)
Analyst
Recommendation
Action
Price target
Projected
Date
Douglas Miehm
RBC Capital
Hold
Reiterated
$9.00
+58.7%
07/30/2026
Glen Santangelo
Barclays
Hold
Reiterated
$7.00
+23.5%
06/03/2026
Les Sulewski
Truist Financial
Hold
Reiterated
-
-
05/01/2026
Michael Nedelcovych
TD Cowen
Hold
Maintained
$7.00
+23.5%
04/30/2026
Umer Raffat
Evercore ISI
Hold
Maintained
-
-
04/30/2026
Jason Gerberry
Bank of America Securities
Sell
Reiterated
$5.00
-11.8%
02/18/2026
Last report
Jul 29, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$1.26 / $1.01
+25.12%beat
Revenue / Est. (USD)
2.85B / 2.66B
+7.25%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.68B
2.80B
2.52B
2.85B
Cost of goods sold
750.00M
798.00M
738.00M
772.00M
Cost of revenue
750.00M
798.00M
738.00M
772.00M
Research and development expenses
166.00M
161.00M
163.00M
173.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
795.00M
880.00M
860.00M
907.00M
Operating expense
1.21B
1.28B
1.26B
1.30B
Total operating expenses
1.96B
2.08B
2.00B
2.08B
Operating income
717.00M
721.00M
521.00M
775.00M
Other non operating income
-
-
-
-
EBT including unusual items
218.00M
56.00M
-1.35B
348.00M
EBT excluding unusual items
313.00M
322.00M
118.00M
383.00M
Income tax expense
37.00M
159.00M
77.00M
88.00M
Effective tax rate
16.97%
283.93%
-5.69%
25.29%
Other operating expenses
-
-
1.00M
-
Net income
179.00M
-112.00M
-1.42B
258.00M
Net profit margin
6.68%
-4.01%
-56.38%
9.05%
Earnings per share
1.16
1.10
0.78
1.26
Interest and investment income
15.00M
9.00M
10.00M
11.00M
Interest expense
-412.00M
-397.00M
-402.00M
-396.00M
Net interest expenses
-397.00M
-388.00M
-392.00M
-385.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.02B
1.01B
816.00M
1.06B
Gain or loss from assets sale
-6.00M
-
-3.00M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps